Therapeutic effect of Zeng Ye decoction on primary Sjögren's syndrome via upregulation of aquaporin‑1 and aquaporin‑5 
expression levels

Wu,Xiaodan; Ren,Changhong; Zhou,Hongwei; Zhang,Lin; Juan,Cheng; Yang,Yong

doi:10.3892/mmr.2014.2208

Therapeutic effect of Zeng Ye decoction on primary Sjögren's syndrome via upregulation of aquaporin‑1 and aquaporin‑5 expression levels

Authors:
- Xiaodan Wu
- Changhong Ren
- Hongwei Zhou
- Lin Zhang
- Cheng Juan
- Yong Yang
View Affiliations

Affiliations: Department of Herbal Medicine, School of Basic Medical Sciences, Beijing University of Chinese Medicine, Beijing 100029, P.R. China, Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, P.R. China, Department of Pathology, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 101121, P.R. China
Published online on: May 2, 2014 https://doi.org/10.3892/mmr.2014.2208
Pages: 429-434

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the curative effect of Zeng Ye decoction on primary Sjögren's syndrome (pSS) and further explore its underlying mechanism involving aquaporin (AQP)‑1 and AQP‑5. The pSS model was established based on the immune induction method, and the saliva flow, submandibular gland index, morphological structures of salivary glands, and AQP‑1 and AQP‑5 protein expression levels in the salivary glands were determined. The saliva flow and the submandibular gland index were significantly reduced in the model group (P<0.01, compared with those in the control group), and significantly increased following interferon (IFN), Zeng Ye decoction extraction (ZYE) and Zeng Ye decoction (ZY) treatment (P<0.01, compared with those of the model group). Submandibular gland atrophy, fibrous tissue hyperplasia and multiple focal lymphocytic infiltration were observed in the model group and were attenuated when subjected to IFN, ZYE and ZY treatment. The AQP‑1 and AQP‑5 expression levels increased following IFN, ZYE and ZY treatment (P<0.01, compared with those of the model group), particularly in the ZYE‑35 group. This result indicated that ZYE had a significant protective effect on pSS via upregulation of the expression levels of AQP‑1 and/or AQP‑5. However, the AQP‑1 expression levels increased and the AQP‑5 expression levels decreased in the model groups compared with those in the control group, which indicated different regulatory pathways of the salivary gland damage on the basis of AQP‑1 and AQP‑5. This study provided a significant reference for the prevention and treatment of pSS.

View Figures

View References

1	Fei YY, Li XM, Lin DF, Li MT, Zhang W, et al: Importance of salivary gland focus score in the diagnosis of Sjögren’s syndrome. Zhonghua Yi Xue Za Zhi. 93:976–979. 2013.(In Chinese).
2	Susić G, Stojanović R, Milić V, Boricić I, Mandić B and Milenković S: Juvenile Sjögren’s syndrome: case report. Srp Arh Celok Lek. 141:228–231. 2013.(In Serbian).
3	Igoe A and Scofield RH: Autoimmunity and infection in Sjögren’s syndrome. Curr Opin Rheumatol. 25:480–487. 2013.
4	Cermak JM, Papas AS, Sullivan RM, Dana MR and Sullivan DA: Nutrient intake in women with primary and secondary Sjögren’s syndrome. Eur J Clin Nutr. 57:328–334. 2003.PubMed/NCBI
5	Nocturne G and Mariette X: Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol. 9:544–556. 2013.
6	Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A and Voulgarelis M: Malignant lymphoma in primary Sjögren’s syndrome: an update on the pathogenesis and treatment. Semin Arthritis Rheum. 43:178–186. 2013.PubMed/NCBI
7	Antero DC, Parra AG, Miyazaki FH, Gehlen M and Skare TL: Secondary Sjögren’s syndrome and disease activity of rheumatoid arthritis. Rev Assoc Med Bras. 57:319–322. 2011.
8	Kovács L, Szodoray P and Kiss E: Secondary tumours in Sjögren’s syndrome. Autoimmun Rev. 9:203–206. 2010.PubMed/NCBI
9	Baurmash HD: Diagnosing primary and secondary Sjögren’s syndrome. J Oral Maxillofac Surg. 62:764–766. 2004.
10	Porola P, Mackiewicz Z, Laine M, Baretto G, Stegaev V, et al: Laminin isoform profiles in salivary glands in Sjögren’s syndrome. Adv Clin Chem. 55:35–59. 2011.
11	Busamia B, Gonzalez-Moles MA, Ruiz-Avila I, Brunotto M, Gil-Montoya JA, et al: Cell apoptosis and proliferation in salivary glands of Sjögren’s syndrome. J Oral Pathol Med. 40:721–725. 2011.PubMed/NCBI
12	Porola P, Laine M, Virtanen I, Pöllänen R, Przybyla BD and Konttinen YT: Androgens and integrins in salivary glands in Sjögren’s syndrome. J Rheumatol. 37:1181–1187. 2010.PubMed/NCBI
13	Szczerba BM, Rybakowska PD, Dey P, Payerhin KM, Peck AB, et al: Type I interferon receptor deficiency prevents murine Sjögren’s syndrome. J Dent Res. 92:444–449. 2013.PubMed/NCBI
14	Nordmark G, Eloranta ML and Ronnblom L: Primary Sjögren’s syndrome and the type I interferon system. Curr Pharm Biotechnol. 13:2054–2062. 2012.
15	Mavragani CP and Crow MK: Activation of the type I interferon pathway in primary Sjögren’s syndrome. J Autoimmun. 35:225–231. 2010.
16	Feng Y, Liu Z, Peng Y, Zhang L, Ju P, et al: Validated LC-MS method for simultaneous quantitation of catalpol and harpagide in rat plasma: application to a comparative pharmacokinetic study in normal and diabetic rats after oral administration of Zeng-Ye-Decoction. Biomed Chromatogr. 27:1503–1510. 2013. View Article : Google Scholar
17	Tang W: Analysis of Warm Diseases. Beijing People’s Medical Publishing House; Beijing: pp. 641963, (In Chinese).
18	Primary and secondary Sjögren’s syndrome. Lancet. 2:730–731. 1984.
19	Amador-Patarroyo MJ, Arbelaez JG, Mantilla RD, Rodriguez-Rodriguez A, Cárdenas-Roldán J, et al: Sjögren’s syndrome at the crossroad of polyautoimmunity. J Autoimmun. 39:199–205. 2012.
20	Baldini C, Talarico R, Tzioufas AG and Bombardieri S: Classification criteria for Sjögren’s syndrome: a critical review. J Autoimmun. 39:9–14. 2012.
21	Tanner K, Roy N, Merrill RM, Kendall K, Miller KL, et al: Comparing nebulized water versus saline after laryngeal desiccation challenge in Sjögren’s Syndrome. Laryngoscope. 123:2787–2792. 2013.PubMed/NCBI
22	Castro I, Sepulveda D, Cortés J, Quest AF, Barrera MJ, et al: Oral dryness in Sjögren’s syndrome patients. Not just a question of water. Autoimmun Rev. 12:567–574. 2013.
23	Wu AJ: The oral component of Sjögren’s syndrome: pass the scalpel and check the water. Curr Rheumatol Rep. 5:304–310. 2003.
24	Steinfeld S, Cogan E, King LS, Agre P, Kiss R and Delporte C: Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest. 81:143–148. 2001.PubMed/NCBI
25	Miyawaki S, Torikai K, Natsume I, Nobunaga T, Ohtsuka E, et al: Evaluation of two quantitative tests for salivary secretion - the chewing gum test and the Saxon test in normal subjects and in patients with Sjögren’s syndrome. Ryumachi. 31:22–27. 1991.(In Japanese).
26	van der Reijden WA, van der Kwaak H, Vissink A, Veerman EC and Amerongen AV: Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjögren’s syndrome. Arthritis Rheum. 39:57–63. 1996.PubMed/NCBI
27	Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X and Tzioufas AG: Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol. 8:399–411. 2012.
28	Simmons DD, Al-Hashimi I and Haghighat N: Effect of xerostomic medications on stimulated salivary flow rate in patients with Sjögren’s syndrome. Quintessence Int. 31:196–200. 2000.PubMed/NCBI
29	Sabapathy K: Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci. 106:145–169. 2012. View Article : Google Scholar : PubMed/NCBI